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Abstract
Background: Patients with multiple endocrine neoplasia type 1 (MEN-1) develop multiple pancreatic neuroendocrine
neoplasias (PNENs). Size at diagnosis and growth during follow-up are crucial parameters. According to the WHO 2017,
grading is another important parameter. The impact of grading compared to size (WHO 2000) on the clinical course
needs to be evaluated.
Methods: Sixty PNENs of six patients with MEN-1 were retrospectively evaluated.
Results: Fifty-one tumors with a diameter of < 20mm were graded as G1. Two of 9 tumors with diameters of ≥20mm
were graded as G2. Tumor size of ≥20mm correlated significantly with higher proliferation (p = 0.000617). Lymph node
metastases were documented in two patients with a total of 19 tumors. In one patient, all 13 tumors (diameter: 0.4 to
100mm) were classified as G1. However, metastases were documented in 9/29 lymph nodes. In the other patient, 5
tumors (3.5 to 20mm) were classified as G1. The sixth tumor (30 mm) was classified as G2 (Ki-67: 8%). Metastases were
revealed in 2/20 lymph nodes.
Conclusions: Tumor size of ≥20mm seems to correlate with more aggressive MEN-1 related pancreatic disease,
regardless of individual proliferation. Tumors ≥20mm and tumors graded as G2 should be treated surgically regardless
of their size.
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Introduction
Patients with multiple endocrine neoplasia type 1 (MEN-1)
develop multiple pancreatic neuroendocrine neoplasias
(PNENs) which show various sizes and may be functioning
(F)- or non-functioning (NF)-PNENs.
Independent of their size mostly F-PNENs are an indica-
tion for surgery in an attempt to control hormone excess.
The majority of (NF)-PNENs are measuring < 20mm with
a low oncologic risk [1, 2]. The treatment ranges from
watchful waiting to partial and total pancreatectomy, the
latter resulting in a diabetic metabolic status [1–6].
NF-PNENs ≥20mm are discussed an indication for surgi-
cal intervention [7].
The “20mm size cut-off” was recommended by the
WHO 2000 [8] based on clinical follow-up studies of
sporadic PNENs showing locally invasive growth as well
as local and distant metastasis more often at the time of
diagnosis and during clinical follow-up. Size is easily
assessed and documented radiologically [9–11], but it
seems to be only one of various potential factors that
determine the biological tumor behavior. Tumor biology
may additionally be characterized by the mitotic count
and proliferation index obtained on tissue samples using
the WHO grading system [12].
The malignant potential of neuroendocrine tumors
(NETs) is divided into three groups (G1, G2 and G3)
according to their proliferation rates, measured by mitotic
count and by the percentage of cells with immunohis-
tochemically expressed Ki-67 (G1: < 3%; G2: 3–20%,
G3: > 20%) [13–15].
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In MEN-1 patients, the impact of PNENs grading in
correlation with size has not been evaluated to plan ei-
ther surveillance or surgery; multiple pubmed searches
yielded no suggestive results with any combinations of
two of the following keywords: MEN-1, multiple endo-
crine neoplasia, pancreas, grading, size, surgery.
Materials and methods
Sixty PNENs belonging to 6 MEN-1 patients (2 females,
age 38 and 61; 4 males, age 15, 29, 33 and 60) were studied
(Table 1).
Informed consent was obtained from all individual
participants included in the study.
All procedures performed in this study were in accord-
ance with the ethical standards of the institutional re-
view board (approval number: 1053/2013) and with the
1964 Helsinki Declaration and its later amendments.
Biochemical and clinical pre- and postoperative staging
Preoperatively the biochemical screening and follow-up
was performed according to the recently revised ENETS
guidelines [16]. In all patients CgA levels were deter-
mined preoperatively and during follow-up.
The number, location and appearance of the PNENs were
evaluated by endoscopic ultrasound (EUS; fine-needle
aspiration cytology was not performed), computerized
tomography (CT), and/or by magnetic resonance im-
aging (MRI) of the pancreas. To exclude distant metastasis
somatostatin-receptor (SSR)-mediated scintigraphy was ap-
plied at the time of diagnosis.
Surgery
The indications for surgery were functioning (n = 3;
organic hyperinsulinism [n = 2; patients D and F], Water
Diarrhea Hypokalemia Achlorhydria (WDHA) syndrome
[n = 1; patient A]) or multiple non-functioning tumors >
20mm (n = 3; patients B, C, E).
Total pancreatectomy was performed in patients A, B, C
and E (patients B and C suffering from insulin-dependent
diabetes mellitus type 2 preoperatively) because of the
large amount of PNENs distributed throughout the pan-
creas without any chance to save “normal” pancreatic tis-
sue. In patient D, a left pancreatic resection was carried
out to save parts of the pancreatic body and the head. In
patient F, a left pancreatic resection was performed and
three PNENs were enucleated from the pancreatic head
(Thompson procedure [17]). Extended lymph node dissec-
tion was performed in all patients. At the time of surgery,
no liver or other distant metastases were documented in
any of the patients (cM0). All operations performed were
open operations.
Immunohistochemistry
Each of the 60 PNENs (functioning and non-functioning)
and all lymph nodes dissected were evaluated histologi-
cally and immunohistochemically.
Staining with chromogranin A (CgA), synaptophysin,
Ki-67, Islet-1, TTF1 and CDX2 was performed.
The tumors were classified according to the WHO
classification of 2017 [14, 17, 18] and staged according to
the European Neuroendocrine Tumor Society (ENETS)
consensus proposal of 2006 and the American Joint Com-
mittee on Cancer (AJCC)/Union for International Cancer
Control (UICC) classification of 2010 [17–19].
Tumor tissue was routinely formalin-fixed and paraffin-
embedded. Hematoxylin and eosin (H&E) staining involved
3 μm sections of each block. One representative block of
each primary tumor and lymph node metastasis was
selected, and 3 μm sections were cut. Immunostainings
with chromogranin A (CgA), synaptophysin and against
Table 1 Mutation, TNM, surgery, Ki-67 (%) of the largest tumor, and follow-up of 6 MEN-1 patients
Patient Mutation Gender Age T N M Ki-67% function Surgery Follow-up
Status
Years
ENETS UICC
A Exon 2, del 4 bp (c.247_250delCTGT);
- > Termination after amino acid 116
m 29 3 2 0 0 2 F (WDHA-Syndrome) TP DF 12
B Intron 4, G > A -9 bp
- > Alternative splicing
f 60 2 2 1 0 8 NF TP PD (M?) 10
C Exon 9, Q405X, CAG > TAG (Gln > Stop)
- > Termination after amino acid 404
m 60 2 2 0 0 2 NF TP DF 7
D Exon 3, Codon 179 GAG>AAG (Glu > Lys)
- > AS Exchange
m 15 2 1 0 0 3 F (Hyper-insulinism) DP DF 29
E Exon 4, p.I247N, ATT > AAT (Ile > Asn)
WORLDWIDE INDEX-CASE
f 38 2 2 0 0 1 NF TP DF [+] 4
F Exon 3, del4bp (amino acid 210/211)
- > Termination after amino acid 209
m 33 3 2 1 0 1 F (subclinical Hyper-
insulinism)
DP, E PD (N) 21
T tumor classification of the largest tumor, N lymph node, Ki-67 Index in %, M distant metastasis, m male, f female
F functioning, NF non-functioning
TP fotal pancreatectomy, DP distal pancreatic resection, E enucleation
DF disease free, PD pogressive disease; [+]: died unrelated to MEN-1
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proliferation marker Ki-67 antigen (MIB-1 monoclonal
mouse, Novocastra, Newcastle, UK; dilution 1:20), CDX2
(1H9 monoclonal mouse, abcam, Cambridge, UK,
undiluted), Islet-1 (1H9 monoclonal mouse, abcam,
Cambridge, UK, dilution 1:400) and TTF-1 (SP141
monoclonal rabbit, Ventana, Tucson, Arizona, USA,
undiluted) were performed using an automatic immunos-
tainer (Ventana Medical Systems Inc., BenchMark® or
BenchMark® ULTRA, Tucson, Arizona, USA). For antigen
retrieval, slides for Ki-67, CDX2 and Islet-1 staining were
boiled with a commercially available puffer (Ventana
Medical Systems Inc., Cell Conditioning 1, Tucson,
Arizona, USA) for 256, 256 and 64 min, respectively.
In case of Ki-67 staining a commercially available
amplification kit (Ventana Medical Systems Inc.,
Amplification Kit, Tucson, Arizona, USA) was used.
The Ki-67 labeling index with antibody MIB-1 was
used for grading and was assessed in 500 tumor cells in
areas in which the highest nuclear labeling was observed
using an eye grid ocular. The classification was as
follows: G1: Ki-67 < 3, G2: Ki-67 3-20, and G3:
Ki-67 > 20%.
Follow-up
All 6 patients were followed clinically and biochemically
4, 7, 10, 12, 21 and 29 years after diagnosis.
Functional imaging by Gallium-DOTANOC-PET-CT
was performed in 4 of 6 patients (patients A, B, C and
F) 7, 10, 12 and 21 years after surgery. Two patients were
clinically cured. However, they refused biochemical and
radiological follow-up examinations 4 (patient E) and 29
(patient D) years after pancreatic surgery, therefore cure
was not definitively documented.
Statistical analysis
Comparisons of the distribution of G2 tumors in the
group of tumors measuring < 20mm and ≥ 20mm and in
various subgroups were performed with the chi-square
test. Statistical significance was set at a p-value of 0.05.
Expression of Islet-1, TTF1 and CDX2 was evaluated
semiquantitatively.
Results
Overall 60 neuroendocrine lesions were documented in
the surgical specimens (details can be seen in Table 2
and Additional file 1: Table S1).
The tumors were distributed all over the organs: 5 in
the pancreatic head, 17 on the junction between the
pancreatic head and body, 10 in the body, 5 on the junc-
tion between the body and tail, 22 in the tail, and one 5
mm tumor originated in the duodenum.
Imaging by CT or MRI served to localize 10 (16.7%)
out of 60 tumors, all measuring ≥10 mm. Five more tu-
mors (5%; between 5 and 9mm) were documented
either by EUS (n = 2) or intraoperative ultrasound
(IOUS; n = 3).
SSR-scintigraphy was negative in all patients (radio-
logically [r] M0) in terms of distant metastasis.
Forty (66.7%) pancreatic lesions (including the single
duodenal lesion) were microadenomas (largest size/diam-
eter: ≤5mm) [18], 11 (18.3%) were NENs between > 6mm
and < 20mm, and 9 (15.0%) tumors were ≥ 20mm, re-
spectively (Table 3).
According to the TNM classification of pancreatic
neuroendocrine tumors issued by the ENETS and AJCC/
UICC [20], 51 (85.0%) were classified as stage I (pT1,
N0, c/rM0), 6 (10%) as IIA (pT2, N0, c/r M0), one as IIB
(pT3, N0, M0 c/r), and 2 (3.3%) as IIIB (anyT, N1, c/
rM0) according to the ENETS staging system. Applying
the AJCC staging system, 51 tumors were staged as IA
(pT1, pN0, c/rM0), 7 tumors as IB (pT2, pN0, c/rM0),
and the two patients with positive lymph nodes as IIB.
Size and proliferation (Ki-67) index
Applying the proliferation marker Ki-67, 58 (96.6%) le-
sions were classified as G1 and two (3%) as G2, respect-
ively. The proliferation rates ranged from 1 to 8%. No
tumor was classified as G3.
All 51 tumors with a diameter < 20mm were graded as
G1. Seven of 9 tumors (size = tumor diameter ≥ 20mm]
were graded as G1 and two as G2, respectively.
Table 3 summarizes the various subgroups of tumors
based on their different tumor diameters.
Comparing the distribution of G2 tumors in groups I
to III (size < 20mm) and in group IV (≥20 mm), signifi-
cantly more G2 tumors were found in group IV (0/51
[0%] vs. 2/9 [22%]; chi-square test: p = 0.000617).
Comparing groups I + II (size ≤10mm) and groups III
+ IV (size > 10mm), significantly more G2 tumors were
found in the group of tumors > 10mm (0/48 [0%] vs. 2/
12 [16.7%]; chi-square test: p = 0.004018).
Significance could also be documented comparing
group I (size ≤5 mm) with groups II to IV (size > 6mm;
0/40 [0%] vs. 2/20 [10%]; chi-square test: p = 0.041932).
Individual analyses of 6 patients and follow-up
In patient A (3 tumors examined in detail), the largest
(80 mm; T3 according to ENETS, T2 according to UICC;
G1, N0) and the second largest tumor (40 mm; Fig. 1)
were by definition classified as vipomas (proven by VIP
expression in more than 70% of the tumor cells; concord-
ant with high blood VIP levels presurgically). Clinically,
the patient suffered from severe WDHA syndrome [21].
Twelve years after total pancreatectomy the patient is free
of neuroendocrine tumor disease, his insulin-dependent
diabetes is well controlled, and he had no complications
secondary to it so far.
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Table 2 Proliferation index (Ki-67) and immunohistochemical staining of Islet-1, TTF1 and CDX2
Patient Function PNEN Location Ki-67 (%) Islet-1 (%) TTF1 (%) CDX2 (%)
A F (WDHA-syndrome) 1 Head 1 +++ + –
2 Body 1 +++ – –
3 Tail 2 +++ – –
B NF 1 Head 2 +++ – –
2 Body 8 +++ – –
3 1 + ++ –
4 1 ++ – –
5 1 +++ – –
6 Tail 1 +++ – –
C NF 1 Duodenum 1 + – ++
2 Head 1 +++ – –
3 Body 1 +++ – ++
4 2 +++ – –
5 1 +++ – –
6 1 +++ – –
7 1 +++ – –
8 Tail 1 +++ – –
9 1 +++ – –
10 1 +++ – –
11 1 +++ – –
12 1 +++ – –
13 1 +++ – –
14 1 +++ – –
15 1 +++ – –
D F (Hyper-insulinism) 1 Body/Tail 1 +++ – –
2 1 +++ – –
3 3 +++ – –
4 2 +++ – –
5 1 +++ – –
E NF 1 Head 1 n.f. n.f. n.f.
2 1 +++ – –
3 Head/Body 1 +++ – –
4 1 +++ – –
5 1 +++ – –
6 1 +++ – –
7 1 +++ – –
8 Tail 1 +++ – –
9 1 +++ – –
10 1 +++ – –
11 1 +++ – –
12 1 +++ – –
13 1 +++ – –
14 1 +++ – –
15 1 +++ – –
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Patient B with 6 PNENs was staged as IIIA. The lar-
gest lesion located in the pancreatic head was a moder-
ately proliferating G2 tumor (Ki-67: 8%; TTF1 positiv)
30 mm in diameter (pT2). The proliferation rate of this
tumor was identical to the two affected regional lymph
nodes (pN1–2/20; Table 4, Ki-67: 6 and 8% in hotspots).
10 years after total pancreatectomy, the Gallium
DOTANOC-PET-CT and MRT revealed multiple small
(≤10mm) liver metastases.
In patient C, 15 tumors were examined, including one
in the duodenum (which was positive for CDX2). The
leading tumor measured 25 mm, corresponding to pT2
N0 cMo. All tumors were graded as G1.
Seven years after total pancreatectomy, the patient is
free of neuroendocrine tumor burden.
Patient D presented with hypoglycemia. Organic hy-
perinsulinism was confirmed clinically and biochemically
in this patient at age 15. Preoperatively, one tumor was
diagnosed in the pancreatic tail (20 mm), while three
others (15, 6, 5 mm) were localized by intraoperative
sonography in the pancreatic body. After left pancreatic
resection, five neuroendocrine neoplasias were described
Table 2 Proliferation index (Ki-67) and immunohistochemical staining of Islet-1, TTF1 and CDX2 (Continued)
Patient Function PNEN Location Ki-67 (%) Islet-1 (%) TTF1 (%) CDX2 (%)
16 1 +++ – –
17 1 +++ – –
18 1 +++ – –
F F (subclinical Hyper-insulinism) 1 Head/Body 1 +++ – –
2 1 +++ – –
3 1 +++ – –
4 1 +++ – –
5 1 +++ – –
6 1 +++ – –
7 1 +++ – –
8 1 +++ – –
9 1 +++ – –
10 1 +++ – –
11 1 +++ – –
12 1 +++ – –
13 Tail 1 +++ – –
Positivity of cells (+: ≤ 10%; ++: > 10 to < 100%; +++: 100%)
Table 3 Correlation of size and grading - Subgroup analysis
pT Group Size (mm) G1 G2 Ʃ %
ENETS AJCC/UICC
1 1 A I ≤5 39 + 1a 0 40 66.7
II 6≤ 10 8 0 8 13.3
III 11 < 20 3 0 3 5.0
2 2 B IV ≥20–40 5 2 7 11.7
3 > 40 2 0 2 3.3
58 2 60 100
P: pathological; T: tumor, size in mm; G: Grading; G1: Ki-67 < 3; G2:
Ki-67 3-20%; aduodenum;
ENETS: European Neuroendocrine Tumor Society
AJCC: American Joint Committee on Cancer; UICC: Union for International
Cancer Control
Group A (tumor diameter < 20 mm) vs group B (tumor
diameter ≥ 20 mm): p = 0.000617
Group I (tumor diameter ≤ 5mm) vs Groups II to IV (> 6mm): p = 0.041932
Groups I + II (tumor diameter ≤ 10mm) vs Groups III + IV
(> 11mm): p = 0.004018
Fig. 1 CT-image of two large tumors (80 mm and 40 mm) of patient
A that were both immunohistochemically positive for VIP
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in final histology. The largest (20 mm) with 3% positivity
for Ki-67 presented by definition as a low G2 NET. More
than 70% of the neuroendocrine cells of this tumor
showed immunopositivity for insulin (=insulinoma).
Twenty-nine years after surgery, the patient is clinically
cured. Now 42 years of age, he refuses any follow-up
examinations.
Seventeen tumors (all smaller than 10mm) were eval-
uated in the specimen obtained from patient E after
total pancreatectomy. None showed a proliferation rate
higher than 1%, corresponding to G1. The original histo-
pathological report described another non-functioning
tumor of 22 mm in diameter (the only one located by
CT preoperatively) in the pancreatic head with a Ki-67
of < 1%. Therefore, the tumor was classified as pT2.
Clinically free of symptoms, she died of liver cirrhosis
based on alcohol abuse four years later.
Patient F had 13 tumors ranging from less than 1 mm
in size to 100mm (!). The large tumor described in CT
was located in the pancreatic tail. All lesions, including
the large one, were graded as G1. At the time of surgery,
lymph node metastases were diagnosed in 9 of 29 lymph
nodes. All lymph nodes were invaded by a G1 tumor.
The patient had (subclinical) hyperinsulinism. Immuno-
histochemically, the largest tumor was negative for insulin,
but some smaller tumors showed insulin-positive neuro-
endocrine cells dispersed (less than 70%) in the lesions.
Twenty-one years after subtotal pancreatic left resection
and enucleation of three pancreatic head tumors and lymph
node dissection, low normal fasting glucose levels corres-
pond to high normal insulin and C-peptide levels. The pa-
tient is free of clinical symptoms. Ga-DOTANOC-PET-CT
reveals multiple lymph node metastases in the upper
abdomen.
Discussion
All NENs are potentially malignant lesions [22]. The ma-
jority of PNENs are histologically well differentiated and
slow-growing tumors that differ in their biological behavior.
In the WHO 2000 classification, NF- and F-tumors (except
insulinoma) were thought to show low-grade malignancy
[23]. Clinical behavior is influenced by various clinical-
pathological features such as size, local−/angioinvasion and
histological differentiation [24].
Currently, the ENETS and the WHO 2017 each propose
a formal classification for PNENs based on proliferative
tumor activity as measured by mitotic count and the ex-
pression of nuclear antigen Ki-67, subdividing the NENs
into G1, G2 and G3, respectively [14, 18]. Grading is com-
bined with site-specific (TNM) staging to improve prog-
nostic strength.
To our knowledge, the prognostic impact of PNEN
grading in correlation to size (pT) has not yet been eval-
uated in MEN-1 because the number of patients with
pancreatic surgery is low. However, as shown here there
seem to be no significant differences in the biological be-
havior of sporadic and hereditary PNENs.
Due to the genetic background of MEN-1, every single
neuroendocrine cell of the pancreas is a potential pro-
genitor of a NEN. Therefore, organs are pervaded by
neuroendocrine micro- and macro-lesions in up to 90%
of genetically affected patients [19]. As expected, the
majority of neuroendocrine lesions in the six MEN-1 pa-
tients were non-functioning and developed predomin-
antly as microadenomas (≤ 5 mm in diameter; 66.7%).
Fifty-eight (96.6%) of the 60 lesions were graded as G1
and two (3.3%) tumors as G2 [14, 18]. No lesion was
graded as G3. G2 tumors were found only in lesions
≥20mm (ENETS/AJCC pT2), while all tumors < 20mm
(ENETS/AJCC pT1) were graded as G1.
Within one pancreatic gland, NENs of various sizes
and different Ki-67 indices were found, demonstrating
intertumor heterogeneity within one patient. These
findings underline the observation that size – an im-
portant parameter for the definition of T in the TNM
classification – appears to be an independent predictor
of survival, and the evaluation of Ki-67 alone cannot be
utilized for this purpose. This is comparable to the situ-
ation in sporadic PNENs [25]. Grading may help to better
estimate metastasizing capacity. As every single tumor is a
potential risk for systemic disease [26], early diagnosis and
surgical excision of MEN-1-related PNENs can improve
survival [3].
Imaging with novel radiolabeled somatostatin analogs
(Ga68-DOTANOC), PET/CT or MRI allows to measure
size, to verify local invasion of the primary tumor(s), and
to evaluate the presence of metastatic disease. Function-
ing imaging is the key element in the management of pa-
tients with MEN-1 to determine appropriate therapeutic
strategies. With regard to our series, somatostatin recep-
tor imaging was performed in all patients and yielded
negative results in respect to distant metastases before
Table 4 Patient B: Size, proliferation and immunohistochemistry
of the primary tumors and lymph node metastasis
PNEN/ LN Location Size (mm) Ki-67
(%)
1 Head 30 8
2 Body 25 1
3 6.3 1
4 4 1
5 3.5 1
6 Tail 20 1
LN 1 8
LN 2 6
PNEN: Pancreatic neuroendocrine neoplasia; LN = lymph node; Grading: G;
G1: Ki-67 <3%; G2: Ki-67 3-20%)
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surgery. During follow up DOPA-Peptide-PET-CTs were
used in all patients and could detect metastatic lesions
in two, which amended the treatment regimens.
The indication, timing and extent of surgery in
NF-PENs has to be individualized on the basis of size
and proliferation activity, keeping in mind the potential
morbidity of pancreatic resection and the risk of
long-term insulin dependence.
Tumor size is easily assessed with EUS or cross-sectional
imaging, while Ki-67 grading on histological samples ob-
tained by EUS-guided fine-needle aspiration is technically
complex [27].
The current analysis is in accordance with some authors
who currently agree that NF-PNENs ≤10mm can be
followed conservatively: all 48 NF-NENs analyzed in this
investigation were graded as G1. The management of
NF-PNENs sized 11 to < 20mm is a matter of debate. The
progression-free survival may be identical in patients under-
going active surveillance compared to surgery [28, 29].
The procedures currently discussed are either resection
or follow-up. Lopez et al. have recommended surgical
treatment for NF-PNENs in MEN-1 with a size between
10 and 20mm, should rapid progression – defined by 5
mm tumor growth annually – be observed [30]. The
current findings indirectly emphasize the recommenda-
tion that NF-PNENs ≥20mm (pT2) should be treated sur-
gically as they likely yield a more aggressive clinical
course, especially if an elevated Ki-67 index is documented
additionally.
Conclusion
This small-scale series with 60 NENs harvested from 6
MEN-1 pancreatic glands adds additional information
regarding the importance of size (pT) in combination with
proliferation (G). In this series, significantly more tumors
≥20mm were classified as G2 (Ki-67 index: > 2 to 20%)
yielding indirectly a higher capacity of malignancy.
When tumors reach the cutoff (20 mm; leading tu-
mors), it may be recommended to obtain tissue speci-
mens of this tumor to select patients at risk of highly
proliferating neoplasms who may require early surgical
intervention to prevent invasive growth, regional and
distant metastasis. PNENs with Ki-67 positive cells > 2%
should probably be treated surgically early on, regardless
of their size.
Additional file
Additional file 1: Table S1. Pancreatic neuroendocrine neoplasia in
MEN-1: Size, TNM, proliferation. A, B, C, E: total pancreatectomy; D: left
pancreatic resection; F: Thompson procedure. (DOCX 22 kb)
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